Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Carbohydrate ingestion results in a fall in glucagon concentration in non-diabetic but not in diabetic individuals. To determine if, and the mechanism by which, lack of postprandial suppression of glucagon contributes to hyperglycaemia, nine subjects with insulin-dependent diabetes mellitus (IDDM) ingested 50 g of glucose containing both [2-3H] glucose and [6-3H] glucose on two occasions. [6-14C] glucose, insulin and low-dose somatostatin were infused intravenously at the same rates on both occasions. A basal glucagon infusion was started either at the same time ("constant glucagon") or 2 h following ("suppressed glucagon") glucose ingestion. This resulted in lower (p < 0.001) glucagon concentrations during the first 2 h of the suppressed than during the constant glucagon study days (63 +/- 1 vs 108 +/- 2 pg/ml). Lack of suppression of glucagon led to higher (p < 0.01) postprandial glucose concentrations (10.3 +/- 0.9 vs 8.1 +/- 0.7 mmol/l) and a greater (p < 0.02) integrated glycaemic response. The excessive rise in glucose was due to higher (p < 0.02) rates of postprandial hepatic glucose release during the constant than during the suppressed glucagon study days, whether measured using either [6-3H] glucose (2.6 +/- 0.2 vs 2.0 +/- 0.2 mmol.kg-1 per 6 h) or [2-3H] glucose (3.0 +/- 0.3 vs 2.4 +/- 0.2 mmol.kg-1 per 6 h) as the meal tracer. Glucose disappearance, initial splanchnic glucose clearance and hepatic glucose cycling did not differ on the two occasions. Thus, the present studies demonstrate that lack of postprandial suppression of glucagon, by increasing hepatic glucose release, contributes to hyperglycaemia in subjects with IDDM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have estimated that postprandial hyperglucagonemia may contribute to ~50% of the pathological increase in plasma glucose levels after glucose ingestion.145–147”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measurement of Size and Turnover Rate of Body Glucose Pool by the Isotope Dilution Method
Steele, R., Wall, J. S., de Bodo, R. C., & Altszuler, N. (1956) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1956.187.1.15 · Cited by 816 · cited 1×
“Glucose turnover was calculated using Steele's non-steady-state equations [20].”
MethodThe Control of Glycogen Metabolism in the Liver
Hers, H. G. (1976) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.45.070176.001123 · Cited by 448
The control of glycogen metabolism in the liver
Hers, H. G., De Wulf, H., & Stalmans, W. (1970) · FEBS Letters · doi:10.1016/0014-5793(70)80569-5 · Cited by 414
Futile Cycles in the Metabolism of Glucose
(1976) · Current Topics in Cellular Regulation · doi:10.1016/b978-0-12-152810-2.50013-9 · Cited by 321 · cited 2×
“Hepatic glucose cycling refers to the concomitant uptake and release of glucose by the liver [27].”
BackgroundMethodFirth, R. G., Bell, P. M., Marsh, H. M., Hansen, I., & Rizza, R. A. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112467 · Cited by 280
Self-citationHyperglucagonemia and Blood Glucose Regulation in Normal, Obese and Diabetic Subjects
Sherwin, R. S., Fisher, M., Hendler, R., & Felig, P. (1976) · New England Journal of Medicine · doi:10.1056/nejm197602262940901 · Cited by 252 · cited 2×
“Changes in portal venous insulin concentrations likely account for previous failures to detect an effect of glucagon on postprandial carbohydrate tolerance in non-diabetic volunteers '[7-9].”
BackgroundRole of glucagon in the pathogenesis of diabetes: The status of the controversy
Unger, R. H. (1978) · Metabolism · doi:10.1016/0026-0495(78)90291-3 · Cited by 216 · cited 6×
“This reciprocal relationship between glucose and gtucagon is abolished by diabetes mellitus [1, 2, 11].”
BackgroundInfluentialA simplified, colorimetric micromethod for xylose in serum or urine, with phloroglucinol.
Eberts, T. J., Sample, R. H., Glick, M. R., & Ellis, G. H. (1979) · Clinical Chemistry · doi:10.1093/clinchem/25.8.1440 · Cited by 199 · cited 1×
“, USA) and D-xylose by a colorimetric assay [18].”
MethodCURRENT TOPICS IN CELLULAR REGULATION
Stadtman, E. R., & Chock, P. B. (1996) · Shock · doi:10.1097/00024382-199609010-00016 · Cited by 179
Metabolic effects of the nocturnal rise in cortisol on carbohydrate metabolism in normal humans.
Dinneen, S., Alzaid, A., Miles, J., & Rizza, R. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116832 · Cited by 175 · cited 4×
“In non-diabetic individuals glucagon concentrations fall as glucose concentrations rise, and rise as glucose concentrations return toward preprandial levels [12-14].”
BackgroundMethodInfluentialSelf-citation
Cited by
Glucagon and regulation of glucose metabolism
Jiang, G., & Zhang, B. B. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00492.2002 · Cited by 905
“A lack of suppression of hyperglucagonemia has also been shown to contribute to postprandial glucose intolerance in type 1 diabetes (26).”
BackgroundBonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670
Gerich, J. E., Meyer, C., Woerle, H. J., & Stumvoll, M. (2001) · Diabetes Care · doi:10.2337/diacare.24.2.382 · Cited by 606
α-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Glucose Metabolism and Regulation: Beyond Insulin and Glucagon
Aronoff, S. L., Berkowitz, K., Shreiner, B., & Want, L. (2004) · Diabetes Spectrum · doi:10.2337/diaspect.17.3.183 · Cited by 569
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Degn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427
“This, combined with an abnormal circadian glucagon secretory pattern (5,33) and diminished ability of hyperglycemia to suppress glucagon secretion, demonstrates the necessity for opposing both the - and -cell malfunction in the treatment of type 2 diabetes.”
BackgroundThe New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“Accordingly, John Gerich (223) demonstrated in 1974 that inhibition of postprandial glucagon secretion through infusion of somatostatin substantially decreased blood glucose in diabetic patients, a seminal observation later confirmed in several independent studies (149, 541, 542).”
ResultPhysiology of the pancreatic α-cell and glucagon secretion: role in glucose homeostasis and diabetes
Quesada, I., Tudurí, E., Ripoll, C., & Nadal, Á. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0290 · Cited by 412
The role of insulin receptors and IGF-I receptors in cancer and other diseases
Frasca, F., Pandini, G., Sciacca, L., Pezzino, V., Squatrito, S., Belfiore, A., & Vigneri, R. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450801969715 · Cited by 410
Dunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369
Shah, P., Vella, A., Basu, A., Basu, R., Schwenk, W. F., & Rizza, R. A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6993 · Cited by 368
Self-citationPancreatic signals controlling food intake; insulin, glucagon and amylin
Woods, S. C., Lutz, T. A., Geary, N., & Langhans, W. (2006) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2006.1858 · Cited by 277
“…glucagon levels are increased in type-2 diabetes mellitus and may contribute to hyperglycemia in both type-1 and type-2 diabetes mellitus (Dinneen et al. 1995), but these changes would seem to predict increased satiety and consequently reduced caloric intake, whereas as discussed above,…”
Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) (2018) · Endocrine Reviews · doi:10.1210/er.2017-00191 · Cited by 262
Minireview: Glucagon in the Pathogenesis of Hypoglycemia and Hyperglycemia in Diabetes
Cryer, P. E. (2012) · Endocrinology · doi:10.1210/en.2011-1499 · Cited by 242
Amylin Agonists: A Novel Approach in the Treatment of Diabetes
Schmitz, O., Brock, B., & Rungby, J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s233 · Cited by 239
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
“Some case reports show a decrease in fasting blood glucose of more than 40% by the end of the first postoperative day, with resolution of T2D and discontinuation of exogenous insulin treat-ment after just 6 days (Pories et al., 1995).”
BackgroundInfluentialKnop, F. K., Vilsbøll, T., Madsbad, S., Holst, J. J., & Krarup, T. (2007) · Diabetologia · doi:10.1007/s00125-006-0566-z · Cited by 193
“By increasing hepatic glucose production, this lack of glucagon suppression contributes significantly to postprandial hyperglycaemia in subjects with type 2 diabetes [5–8].”
BackgroundGromada, J., Bokvist, K., Ding, W.-G., Barg, S., Buschard, K., Renström, E., & Rorsman, P. (1997) · The Journal of General Physiology · doi:10.1085/jgp.110.3.217 · Cited by 187
Impact of lack of suppression of glucagon on glucose tolerance in humans
Shah, P., Basu, A., Basu, R., & Rizza, R. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.2.e283 · Cited by 164
Self-citationHydrogels in Emerging Technologies for Type 1 Diabetes
Fuchs, S., Ernst, A. U., Wang, L., Shariati, K., Wang, X., Liu, Q., & Ma, M. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01062 · Cited by 169
Roden, M., Perseghin, G., Petersen, K. F., Hwang, J., Cline, G. W., Gerow, K., Rothman, D. L., & Shulman, G. I. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118460 · Cited by 169
Levetan, C. S., Want, L. L., Weyer, C., Strobel, S. A., Crean, J., Wang, Y., Maggs, D. G., Kolterman, O., Chandran, M., Mudaliar, S. R., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.1 · Cited by 162
“This is attributable not only to a failure to achieve the normally high portal vein insulin concentrations with subcutaneously injected insulin, but also to the fact that many patients with type 1 diabetes have an impaired suppression of, or even a paradoxical increase in, glucagon concentrations postprandially (24).”
BackgroundTargeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 156
Kielgast, U., Holst, J. J., & Madsbad, S. (2011) · Diabetes · doi:10.2337/db10-1790 · Cited by 137
“Even though lack of insulin is considered to be the most important factor for the hyperglycemia in type 1 diabetic patients, other metabolic disturbances may also play a role: the glucagon response to carbohydrate and protein ingestion has been shown to be abnormal (7) and there is evidence that postprandial hyperglyc…”
BackgroundGlucagon and Type 2 Diabetes: the Return of the Alpha Cell
Lund, A., Bagger, J. I., Christensen, M., Knop, F. K., & Vilsbøll, T. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0555-4 · Cited by 144
Exendin-4 Normalized Postcibal Glycemic Excursions in Type 1 Diabetes
Dupré, J., Behme, M. T., & McDonald, T. J. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032001 · Cited by 133
Denroche, H. C., Levi, J., Wideman, R. D., Sequeira, R. M., Huynh, F. K., Covey, S. D., & Kieffer, T. J. (2011) · Diabetes · doi:10.2337/db10-0958 · Cited by 130
Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes
Ali, S., & Drucker, D. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90887.2008 · Cited by 130
“Subjects with type 2 diabetes mellitus (T2DM) have fasting hyperglucagonemia with impaired postprandial glucagon suppression in the presence of defective insulin secretion and/or action.”
InfluentialLiu, Y.-J., Vieira, E., & Gylfe, E. (2004) · Cell Calcium · doi:10.1016/j.ceca.2003.10.002 · Cited by 118
Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis
Ali, S., Lamont, B. J., Charron, M. J., & Drucker, D. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43615 · Cited by 119
Weyer, C., Gottlieb, A., Kim, D. D. H., Lutz, K., Schwartz, S. L., Gutiérrez, M. E. H., Wang, Y., Ruggles, J. A., Kolterman, O., & Maggs, D. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3074 · Cited by 108
Quesada, I., Todorova, M. G., Alonso-Magdalena, P., Beltrá, M., Carneiro, E. M., Martin, F., Nadal, A., & Soria, B. (2006) · Diabetes · doi:10.2337/db06-0272 · Cited by 104
“The hyperglycemia provoked by diabetes is mainly caused by a malfunction of insulin secretion from -cells or an adaptation to increased peripheral demand (16), although a disturbed secretion of glucagon from -cells may exacerbate it (17,18).”
BackgroundFrandsen, C. S., Dejgaard, T. F., Holst, J. J., Andersen, H. U., Thorsteinsson, B., & Madsbad, S. (2015) · Diabetes Care · doi:10.2337/dc15-1037 · Cited by 103
Nyholm, B., Ørskov, L., Hove, K. Y., Gravholt, C. H., Møller, N., George, K., Alberti, M. M., Moyses, C., Kolterman, O., & Schmitz, O. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90232-9 · Cited by 104
Function and expression of somatostatin receptors of the endocrine pancreas
Strowski, M. Z., & Blake, A. D. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.02.007 · Cited by 118
“Hyperglucagonemia further exacerbates hyperglycemia Page 7 of 29 Ac ce pt ed M an us cr ip t 7 through stimulation of hepatic glucose production (Ohneda et al., 1978; Dinneen et al., 1995; Shah et al., 2000; Unger and Orci 1975; Unger 1975).”
BackgroundPost-prandial hyperglycemia. post-prandial hyperglycemia and diabetes.
Gin, H., & Rigalleau, V. (2000) · PubMed · Cited by 135
Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus
Frandsen, C. S., Dejgaard, T. F., & Madsbad, S. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00039-5 · Cited by 101
Ahr�n, B., & Larsson, H. (2001) · Diabetologia · doi:10.1007/s001250100003 · Cited by 95
Insulin and Glucagon: Partners for Life
Holst, J. J., Holland, W. L., Gromada, J., Lee, Y., Unger, R. H., Yan, H., Sloop, K. W., Kieffer, T. J., Damond, N., & Herrera, P. L. (2017) · Endocrinology · doi:10.1210/en.2016-1748 · Cited by 100
“Hyperglucagonemia and dysregulated glucagon secretion have been implicated in contributing to hyperglycemia in patients with type 1 (1, 2) and type 2 (3–5) diabetes mellitus.”
BackgroundBasu, A., Alzaid, A., Dinneen, S. F., Caumo, A., Cobelli, C., & Rizza, R. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118678 · Cited by 90
Self-citationObesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges
Vilarrasa, N., José, P. S., Rubio, M. Á., & Lecube, A. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s223618 · Cited by 111
Glucagon and Glucagon-Like Peptide Receptors as Drug Targets
Estall, J. L., & Drucker, D. J. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206776873671 · Cited by 96
“Persistently elevated levels of glucagon or increased glucagon/insulin ratios are often observed in diabetic humans and in animal models of diabetes [39, 40], and most likely play a substantial role in the development of hyperglycemia, the metabolic signature of both type 1 and type 2 diabetes [38, 41, 42].”
BackgroundWhat Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?
Kuhre, R. E., Deacon, C. F., Holst, J. J., & Petersen, N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.694284 · Cited by 93
Clinical Implications of Amylin and Amylin Deficiency
Kruger, D. F., Gatcomb, P., & Owen, S. K. (1999) · The Science of Diabetes Self-Management and Care · doi:10.1177/014572179902500310 · Cited by 79
Islet amyloid polypeptide: Another key molecule in Alzheimer’s pathogenesis?
Zhang, Y., & Song, W. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.03.001 · Cited by 83
“However, many studies have discovered that dysregulation of glucagon secretion plays a pathological role in the progression of diabetes by inducing hyperglycemia (Dinneen et al., 1995; Shah et al., 2000).”
BackgroundRegulation of hepatic and peripheral glucose disposal
Moore, M. C., Cherrington, A. D., & Wasserman, D. H. (2003) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/s1521-690x(03)00036-8 · Cited by 96
Henkel, E., Menschikowski, M., Koehler, C., Leonhardt, W., & Hanefeld, M. (2005) · Metabolism · doi:10.1016/j.metabol.2005.03.024 · Cited by 81
Buse, J. B., Weyer, C., & Maggs, D. G. (2002) · Clinical Diabetes · doi:10.2337/diaclin.20.3.137 · Cited by 78
Wang, W., Liu, H., Xiao, S., Liu, S., Li, X., & Yu, P. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0282-3 · Cited by 70
“However, insulin cannot improve the excessive secretion of glucagon in patients with T1DM [2].”
BackgroundKruger, D. F., & Gloster, M. (2004) · Drugs · doi:10.2165/00003495-200464130-00003 · Cited by 78
Glycaemic effects of incretins in Type 1 diabetes mellitus
Dupre, J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.003 · Cited by 72
The Alpha-Cell as Target for Type 2 Diabetes Therapy
Christensen, M., Bagger, J. I., Vilsbøll, T., & Knop, F. K. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.369 · Cited by 68
“Rev Diabet Stud (2011) 8:369-381 Copyright © by Lab & Life Press/SBDR postabsorptive hyperglucagonemia can be regarded as responsible for ∼ 50% of the pathological increment in plasma glucose excursions following oral glucose ingestion in diabetics [22-24].”
BackgroundPancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the Block
Moon, J. S., & Won, K. C. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.1.1 · Cited by 61
“In usual case of T2D, plasma glucagon level is often increased and it suggested contributing to the development of glucose toxicity and exacerbation of diabetes [17-21].”
BackgroundLoss of mTORC1 signaling alters pancreatic α cell mass and impairs glucagon secretion
Bozadjieva-Kramer, N., Blandino-Rosano, M., Chase, J., Dai, X., Cummings, K., Gimeno, J., Dean, E. D., Powers, A. C., Gittes, G. K., Rüegg, M. A., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90004 · Cited by 65
Jun, L. S., Millican, R. L., Hawkins, E. D., Konkol, D. L., Showalter, A. D., Christe, M. E., Michael, M. D., & Sloop, K. W. (2015) · Diabetes · doi:10.2337/db14-1052 · Cited by 60
“The effect of excess glucagon is significant because of the broad stimulatory actions glucagon has on catabolic processes in the liver and the hyperglucagonemia that is present in poorly controlled diabetes (8,9).”
BackgroundMethodResultInfluentialNielsen, M. F., Caumo, A., Aagaard, N. K., Chandramouli, V., Schumann, W. C., Landau, B. R., Schmitz, O., & Vilstrup, H. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00278.2004 · Cited by 61
Sonne, N., Karsdal, M. A., & Henriksen, K. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101109 · Cited by 63
Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists
Kielgast, U. L., Holst, J. J., & Madsbad, S. (2009) · Current Diabetes Reviews · doi:10.2174/157339909789804413 · Cited by 59
“Indeed, it has been shown that in patients with type 1 diabetes, lack of suppression of glucagon during a meal contributes to postprandial hyperglycemia [14].”
Hepatic TRAF2 Regulates Glucose Metabolism Through Enhancing Glucagon Responses
Chen, Z., Sheng, L., Shen, H., Zhao, Y., Wang, S., Brink, R. A., & Rui, L. (2012) · Diabetes · doi:10.2337/db11-0474 · Cited by 58
Kramer, C. K., Zinman, B., Choi, H., Connelly, P. W., & Retnakaran, R. R. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2725 · Cited by 56
Nutrient regulation of glucagon secretion: involvement in metabolism and diabetes
Marroquí, L., Alonso‐Magdalena, P., Merino, B., Fuentes, E., Nadal, Á., & Quesada, I. (2014) · Nutrition Research Reviews · doi:10.1017/s0954422414000031 · Cited by 59
“patients, which further exacerbates their high glucose levels during postprandial periods((167,168)).”
BackgroundBlockade of Na+ Channels in Pancreatic α-Cells Has Antidiabetic Effects
Dhalla, A. K., Yang, M., Ning, Y., Kahlig, K. M., Krause, M., Rajamani, S., & Belardinelli, L. (2014) · Diabetes · doi:10.2337/db13-1562 · Cited by 53
“This hyperglucagonemia increases hepatic glucose production, thereby contributing importantly to diabetic hyperglycemia (4,5).”
Tudurí, E., Filiputti, E., Carneiro, E. M., & Quesada, I. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00641.2007 · Cited by 53
“glycemia derived from -cell malfunction (9, 46).”
BackgroundInfluentialGlucagon as a Critical Factor in the Pathology of Diabetes
Edgerton, D. S., & Cherrington, A. D. (2011) · Diabetes · doi:10.2337/db10-1594 · Cited by 55
“Reduction of glucagon in pancreatectomized canines caused a marked decrease in hepatic glucose production (8) and suppression of glucagon in diabetic humans improved glucose tolerance (9,10).”
BackgroundNovel Pharmacologic Agents for Type 2 Diabetes
Uwaifo, G. I., & Ratner, R. E. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2004.11.006 · Cited by 51
“It has been observed that in subjects who have type 1 and insulin deficient type 2 diabetes, postprandial hyperglucagonemia and hepatic glucose production are exaggerated [24,25].”
BackgroundInhibiting or antagonizing glucagon: making progress in diabetes care
Lefèbvre, P. J., Paquot, N., & Scheen, A. J. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12480 · Cited by 46
“Numerous studies have shown that failure of glucagon suppression contributes to postprandial hyperglycaemia in type 1 [9,10] and type 2 diabetes [11,12].”
BackgroundPieber, T. R., Deller, S., Korsatko, S., Jensen, L., Christiansen, E., Madsen, J. C., & Heller, S. R. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12473 · Cited by 47
“Among other mechanisms, GLP-1 receptor agonists act by inhibiting glucagon secretion in the postprandial state, thereby improving glycaemic control [3,11].”
BackgroundSingh, V., Grötzinger, C., Nowak, K. W., Zacharias, S., Göncz, E., Pleß, G., Sauer, I. M., Eichhorn, I., Pfeiffer-Guglielmi, B., Hamprecht, B., et al. (2007) · Endocrinology · doi:10.1210/en.2006-1659 · Cited by 54
Pullakhandam, R., Palika, R., Ghosh, S., & Reddy, G. B. (2012) · IUBMB Life · doi:10.1002/iub.1096 · Cited by 42
“Interestingly, in contrast to insulin, glucagon levels are reported to be high in both T1D and T2D states, and there is lack of suppression of glucagon release in hyperglycemic conditions, which would further contribute to the postprandial hyperglycemia (56, 57).”
BackgroundGlucagon’s effect on liver protein metabolism in vivo
Kraft, G., Coate, K. C., Winnick, J. J., Dardevet, D. P., Donahue, E. P., Cherrington, A. D., Williams, P. E., & Moore, M. C. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00045.2017 · Cited by 43
“PREVIOUS RESEARCH has shown that subjects with Type 2 diabetes mellitus (T2DM) have high fasting plasma glucagon levels and impairment of glucagon suppression in response to glucose (16), which contributes to the hyperglycemia observed in T2DM following a meal.”
Frandsen, C. S., Dejgaard, T. F., Andersen, H. U., Holst, J. J., Hartmann, B., Thorsteinsson, B., & Madsbad, S. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12830 · Cited by 46
Glucagon: The effects of its excess and deficiency on insulin action
Fanelli, C. G., Porcellati, F., Rossetti, P., & Bolli, G. B. (2006) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2005.10.018 · Cited by 48
Yip, L., Taylor-Edwards, C., Whiting, C. C., & Fathman, C. G. (2013) · Diabetes · doi:10.2337/db13-0614 · Cited by 43
“This induced hyperglucagonemia increases hepatic glucose release and exacerbates postprandial hyperglycemia (6).”
BackgroundGIP’s involvement in the pathophysiology of type 2 diabetes
Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170178 · Cited by 35
Tanday, N., Irwin, N., Flatt, P. R., & Moffett, R. C. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114009 · Cited by 36
Glucagon Response to Oral Glucose Challenge in Type 1 Diabetes: Lack of Impact of Euglycemia
Kramer, C. K., Borgoño, C. A., Nostrand, P. V., Retnakaran, R. R., & Zinman, B. (2013) · Diabetes Care · doi:10.2337/dc13-2339 · Cited by 34
“In addition, experimental studies that evaluated glucagon response to OGTT have also demonstrated an abnormal increase in glucagon after carbohydrate ingestion (8,11).”
BackgroundNeumann, U. H., Ho, J. S. S., Chen, S., Tam, Y. Y. C., Cullis, P. R., & Kieffer, T. J. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.012 · Cited by 38
“Plasma insulin (Mouse Ultrasensitive Insulin ELISA, ALPCO, Salem, NH, USA), glucagon (Glucagon ELISA, Mercodia, Salem, NC, USA), leptin (Mouse Leptin ELISA, Crystal Chem, Downers Grove, IL, USA), b-hydroxybutyrate (b-Hydroxybutyrate LiquiColor Test, Stanbio, Boerne, TX, USA), free fatty acids (HR Series NEFA HR[2] Kit…”
BackgroundMethodBasu, A., Pieber, T. R., Hansen, A. K., Sach‐Friedl, S., Erichsen, L., Basu, R., & Haahr, H. L. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13270 · Cited by 38
“It has been shown both in T1D and T2D that lack of postprandial suppression of glucagon contributes to hyperglycaemia via elevated hepatic glucose release.(24,25) In the present trial, the postprandial increase in glucagon was slightly less for faster aspart than for IAsp (Figure 1D), which may have contributed to the…”
BackgroundNew Insights into Glucose Regulation
Kruger, D. F., Martin, C. L., & Sadler, C. E. (2006) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721706286568 · Cited by 38
Rationale Use of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes
Unger, J. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0404-x · Cited by 30
Kim, M., Park, H. K., Byun, D. W., Suh, K. I., & Hur, K. Y. (2013) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2013.09.008 · Cited by 30
“This lack of glucagon suppression contributes significantly to postprandial hyperglycemia in T2DM patients.(37,38) Also, GIP is unable to further amplify the insulinotropic and glucose-lowering effects of GLP-1 in T2DM patients.”
BackgroundGlucagon Resistance and Decreased Susceptibility to Diabetes in a Model of Chronic Hyperglucagonemia
Bozadjieva-Kramer, N., Lubaczeuski, C., Blandino-Rosano, M., Barker, G. P., Gittes, G. K., Caicedo, A., & Bernal‐Mizrachi, E. (2020) · Diabetes · doi:10.2337/db20-0440 · Cited by 32
Shen, N., Jiang, S., Lu, J., Yu, X., Lai, S., Zhang, J., Zhang, J.-L., Tao, W.-W., Wang, X., Xu, N., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.10.016 · Cited by 35
Lee, M., Kim, M., Park, J. S., Lee, S., You, J. H., Ahn, C. W., Kim, K. R., & Kang, S. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.233 · Cited by 31
“Several papers have found glucagon excess to be an independent pathogenesis from insulin resistance in type 2 diabetes [13,39,40], and hyperglucagonemia has been continually detected in diabetic patients without obesity [31].”
BackgroundPax6 Is a Key Component of Regulated Glucagon Secretion
Gosmain, Y., Cheyssac, C., Masson, M. H., Guérardel, A., Poisson, C., & Philippé, J. (2012) · Endocrinology · doi:10.1210/en.2012-1425 · Cited by 36
Intercellular Communication in the Islet of Langerhans in Health and Disease
Ng, X. W., Chung, Y. H., & Piston, D. W. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200026 · Cited by 43
Molecular Pathways Underlying the Pathogenesis of Pancreatic α-Cell Dysfunction
Kawamori, D., Welters, H. J., & Kulkarni, R. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-3271-3_18 · Cited by 27
Sloan, J. H., Siegel, R. W., Ivanova-Cox, Y. T., Watson, D. E., Deeg, M. A., & Konrad, R. J. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.07.111 · Cited by 29
Beis, C., Grigorakis, S. I., Philippou, G., Alevizaki, M. K., & Anastasiou, E. (2005) · Acta Diabetologica · doi:10.1007/s00592-005-0171-5 · Cited by 26
“In a variety of pathophysiological states related to an impairment of insulin action, known as insulin resistance states, α-cell dysfunction and inappropriately high glucagon levels have been observed, which may further contribute to glucose metabolism disturbance [ 2 , 3]. Therefore, it has been suggested that the in…”
BackgroundØrskov, L., Nyholm, B., Hove, K. Y., Gravholt, C. H., Møller, N., & Schmitz, O. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00162.x · Cited by 25
Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes
Galderisi, A., Sherr, J., VanName, M., Carria, L., Zgorski, M., Tichy, E., Weyman, K., Cengiz, E., Weinzimer, S., & Tamborlane, W. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02265 · Cited by 25
Effects of glucagon on postpranidal carbohydrate metabolism in nondiabetic humans
Frank, J. W., Camilleri, M., Thomforde, G. M., Dinneen, S. F., & Rizza, R. A. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90185-8 · Cited by 25
Self-citationStrowski, M. Z., Cashen, D. E., Birzin, E. T., Yang, L., Singh, V., Jacks, T. M., Nowak, K. W., Rohrer, S. P., Patchett, A. A., Smith, R. G., et al. (2006) · Endocrinology · doi:10.1210/en.2006-0274 · Cited by 27
Amiel, S. A., Heller, S. R., Macdonald, I. A., Schwartz, S. L., Klaff, L. J., Ruggles, J. A., Weyer, C., Kolterman, O., & Maggs, D. G. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00417.x · Cited by 25
Advancements of Biomacromolecular Hydrogel Applications in Food Nutrition and Health
Ye, Z., Sun, L., Xiang, Q., Hao, Y., Liu, H., He, Q. Z., Yang, X., & Liao, W. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c05903 · Cited by 25
Yang, K., Hashemi, Z., Han, W., Jin, A., Yang, H. K., Ozga, J. A., Li, L., & Chan, C. B. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.03.002 · Cited by 25
“The 60- to 120-min phase of the ITT reflects the counterregulatory response, the strength of which is dictated, in part, by the suppressive effect of insulin versus the positive effect of glucagononhepatic glucose production [55].”
BackgroundHigh-fat diet impacts more changes in beta-cell compared to alpha-cell transcriptome
Dusaulcy, R., Handgraaf, S., Visentin, F., Howald, C., Dermitzakis, E. T., Philippé, J., & Gosmain, Y. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213299 · Cited by 29
Jeha, G. S., & Heptulla, R. A. (2006) · Pediatric Diabetes · doi:10.1111/j.1399-543x.2006.00159.x · Cited by 22
Can Postprandial Blood Glucose Excursion Be Predicted in Type 2 Diabetes?
Franc, S., Dardari, D., Peschard, C., Riveline, J., Biedzinski, M., Boucherie, B., Petit, C., Requeda, E., Mistretta, F., Varroud-Vial, M., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0115 · Cited by 22
“In type 2 diabetic subjects, insulin resistance is mostly due to an absence of glucagon prandial secretion suppression (20), leading to an increase in hepatic glucose production (21).”
Background
Metadata
- Authors
- Dinneen, S., Alzaid, A., Turk, D., & Rizza, R.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Dinneen, S.
- Venue
- Diabetologia
- Published
- 1995-03
- Volume
- 38
- Issue
- 3
- Pages
- 337-343
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2068377236
- Cited by
- 190
- References
- 38
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 8 · 2023: 5 · 2022: 5 · 2021: 13 · 2020: 8 · 2019: 3 · 2018: 7 · 2017: 12 · 2016: 10 · 2015: 10 · 2014: 11 · 2013: 5 · 2012: 7
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- Mayo Foundation for Medical Education and Research
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 29953)
- National Center for Research Resources (RR-00585, M01RR000585)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucagon suppression, postprandial hyperglycemia, type 1 diabetes, hepatic glucose production, glucagon, glucose ingestion, somatostatin, glucose clearance
- MeSH terms
- Adult, Blood Glucose, Carbon Radioisotopes, Diabetes Mellitus, Type 1, Dietary Carbohydrates, Eating, Female, Glucagon, Glucose, Humans, Hyperglycemia, Infusions, Intravenous, Insulin, Kinetics, Liver, Male, Portal System, Radioisotope Dilution Technique, Somatostatin, Time Factors, Tritium
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.